SHARE
Allergy Immunotherapy Market

Allergy Immunotherapy Market Forecasts to 2028 – Global Analysis By Allergy Type (Allergic Asthma, Allergic Rhinitis and Others), Allergen (House Dust Mites, Mould and Others) Treatment Type, Distribution Channel and By Geography

4.9 (99 reviews)
Published: August 2021 ID: SMRC20877
4.9 (99 reviews)
Published: August 2021 ID: SMRC20877

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Allergy Immunotherapy Market is accounted for $1.74 billion in 2020 and is expected to reach $4.02 billion by 2028 growing at a CAGR of 11.0% during the forecast period. Advancements in sublingual immunotherapy formulations, growth in the prevalence of allergic disorders and strong product pipeline for novel approaches of treatments are driving the market growth. However, limitation and drawback associated with the use of allergy immunotherapy is hampering the growth of the market.

Allergy immunotherapy is a protective medical treatment for allergic reactions to allergens including various drugs, house dust mites, foods, bee venom and grass pollens. It regulates the response of immune system by gradually increasing the doses of the allergen. This process is also termed as desensitization or hypo-sensitization.

Based on the treatment type, the subcutaneous immunotherapy (SCIT) (specific immunotherapy (SIT)) segment is going to have lucrative growth during the forecast period due to its cost effectiveness and ease of availability of allergy shots. Surge in prevalence of asthma and insect sting allergies are also factors contributing to the growth of segment.

By geography, Europe is going to have high growth during the forecast period as it is a home to a large patient pool which is prone to allergies and thus requires high medical attention. Furthermore, the mount in the instances of approvals of allergy drops will further catapult the progression of the market.

Some of the key players profiled in the Allergy Immunotherapy Market include Adamis, Pharmaceuticals Corporation, ALK-Abello A/S, Allergy Therapeutics, ASIT Biotech, Circassia, DBV Technologies SA, DESENTUM OY, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, Merck KGaA, Mylan N.V. and Stallergenes Greer plc.

Report Coverage

Details

Published Year:

2021

Estimated Market Size in 2020:

USD 1.74 billion

Estimated Period:

2020

Compound Annual Growth Rate (CAGR) from 2020 to 2028:

11.0%

Predicted 2028 Value:

USD 4.02 billion

Forecast Years:

2021-2028

Tables, Graphs & Figures

276

Chapters Covered:

Allergy Type, Allergen, Treatment Type, Distribution Channel and Region

Core Drivers and Opportunities:

  • Advancements in sublingual immunotherapy formulations
  • Growth in the prevalence of allergic disorders
  • Strong product pipeline for novel approaches of treatments

Restraining Factors & Market Threats:

  • Limitation and drawback associated with the use of allergy immunotherapy
  • Side-effects associated with treatment


Allergy Types Covered:
• Allergic Asthma
• Allergic Conjunctivitis
• Allergic Rhinitis
• Atopic Dermatitis
• Food Allergy
• Pet Allergy
• Venom Allergy
• Other Allergy Types

Allergens Covered:
• House Dust Mites
• Mould
• Pollens
• Stinging Insect Venom
• Animal Dander
• Cockroaches/Insects  

Treatment Types Covered:
• Subcutaneous Immunotherapy (SCIT) (Specific Immunotherapy (SIT))
• Sublingual Immunotherapy (SLIT)  

Distribution Channels Covered:
• Institutional Sales
• Retail Sales

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Key Questions Answered In The Report

The Global Allergy Immunotherapy Market is majorly driven by advancements in sublingual immunotherapy formulations, growth in the prevalence of allergic disorders and strong product pipeline for novel approaches of treatments.

The sublingual immunotherapy (SLIT) segment is growing at a highest CAGR as it is an essential alternative for patients who cannot receive allergy shots and hence the adoption is more.

Europe dominated with a significant market share due to the factors such as strong presence of leading market players and increase in population suffering from allergic disorders.

Asia Pacific market is growing at a highest CAGR owing to the investments of leading companies for various functions of immunotherapy leading to growth of the market.

Key players in Allergy Immunotherapy Market include Adamis, Pharmaceuticals Corporation, ALK-Abello A/S, Allergy Therapeutics, ASIT Biotech, Circassia, DBV Technologies SA, DESENTUM OY, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, Merck KGaA, Mylan N.V. and Stallergenes Greer plc.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials